Clinical Trials

We are leaders in the field of oncology

Northwest Oncology takes pride in being the leader in the field of oncology. Clinical trials are an essential process in finding new treatments and surgical procedures and detecting, preventing or treating new diseases.

We are affiliated with various organizations such as: the National Surgical Adjuvant Breast and Bowel Program (NSABP), Gynecologic Oncology Group (GOG), Hoosier Oncology Group (HOG), and Cancer Trials Support Unit (CTSU).

Affiliations

  • Federal clinical research sponsored by the National Surgical Adjuvant Breast and Bowel Program (NSABP) for breast and colon cancer.
  • Federal clinical research sponsored by the Gynecologic Oncology Group (GOG) for gynecological cancers.
  • Phase II clinical trials sponsored by the Hoosier Oncology Group (HOG) for a variety of metastatic cancers.
  • Phase III clinical trials sponsored by the Cancer Trials Support Unit (CTSU) supported by the National Cancer Institute.

Our Clinical Trials

Explore our cancer clinical trials programs below:

High Risk Breast Cancer

Status: On Hold

Protocol Title: A211102
Testing for Atypia in Random Perareolar Fine Needle Aspiration (RPFNA) Cytology after 12 months Metformin (1, 1-Dimethylbigunide Hydorchloride) Chemoprevention versus Placebo Control in Premenopausal Women.

Screening Breast Cancer

Status: Active

Protocol Title: EA1151
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Breast Cancer (Adjuvant)

Status: Active

Protocol Title: A011401
Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Breast Cancer (Adjuvant)

Status: Active

Protocol Title: A011502
A Randomized Phase III Double-Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial.

Breast Cancer (Triple Negative)

Status: Active

Protocol Title: ECOG EA1131
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast cancer following Neoadjuvant Chemotherapy

Breast Cancer (Triple Negative)

Status: Active

Protocol Title: NRG BR003
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Metastatic Triple Negative Breast Cancer

Status: Active

Protocol Title: NRG BR004
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Breast Cancer (Metastic HER2+)

Status: Active

Protocol Title: Daiichi Sankyo, Inc/ DS8201-301
A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibiody drug conjugate, versus treatment of investigator's choice for HER2-positvie, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1

Lung (Adjuvant)-NSLC, tissue study for ALK or EGFR

Status: Active

Protocol Title: ALCHEMIST (A151216)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

Lung (Adjuvant)-NSCLC if ALK + for A151216 study

Status: Active

Protocol Title: ALCHEMIST (E4512)
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.

Lung (Adjuvant)-NSCLC, State IB-IIIA,If EGFR + in A151216 study

Status: Active

Protocol Title: ALCHEMIST (A081105)
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Ovarian (Stage II or IV)

Status: Active

Protocol Title: NRG GY005
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or standard of care chemotherapy in women with recurrent platinum-resistant or refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)

Cervical Cancer (Locally Advanced)

Status: Coming June/July 2020

Protocol Title: MK3475-A18/ ENGOT-cx11
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy with or without Pembrolizumab For The Treatment of High-Risk, Locally Advanced Cervical Cancer (KEYNOTE-A18/ENGOT-cx11)

Head/Neck Cancer

Status: Coming June/July 2020

Protocol Title: EA3161
A Phase II/III Randomized Study of maintenance Nivolumab versus Obversation In Patient with Locally Advanced, Intermediate Risk HPV positive OPCA (oral pharangeal cancer)

High Risk Breast Cancer

Status: Coming June/July 2020

Protocol Title: Caris
Biorespoistory-Prep-Breast Biopsy

Your Own Medical Care Starts Here

Newly Diagnosed? In treatment? Living with a history of cancer? A young adult? No matter where you’re at in your fight, Northwest Oncology can help. Make an appointment below and someone from our staff will contact you.